Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HoloCyt

Financiado

Cerrado

A rapid low cost cervical cancer screening platform

Cervical cancer causes 13.000 deaths and 34.000 new cases in the European Union. 200M tests are performed worldwide per year representing a $3,4B market. Today two tests are performed to diagnose cervical cancer. Firstly, a cervi... ver más

30/06/2017

OVIZIO

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

OVIZIO IMAGING SYSTEMS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-06-30

SMEInst-05-2016-2017: Supporting innovative SMEs in the h...

I+D

Cerrada hace 8 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

OVIZIO

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

HPV OncoPredict A Groundbreaking Stand Alone Diagnostic Kit to Predict Human... 3M€ Cerrado

VALID-SCREEN Validation of PreCursor M for enhanced Cervical Pre Cancer... 3M€ Cerrado

SixthSense Early diagnosis of cervical cancer through the validation of... 71K€ Cerrado

CHILI A Community based HPV screening implementation in Low Income... 3M€ Cerrado

MIMICS MicroRNA Isoforms for Molecular Interception of Cervical can... 150K€ Cerrado

VALPAS VALidation of human PApilloma virus assays on Self collected... 71K€ Cerrado

Duración del proyecto: 6 meses Fecha Inicio: 2016-12-09
Fecha Fin: 2017-06-30

Líder del proyecto

OVIZIO IMAGING SYSTEMS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cervical cancer causes 13.000 deaths and 34.000 new cases in the European Union. 200M tests are performed worldwide per year representing a $3,4B market. Today two tests are performed to diagnose cervical cancer. Firstly, a cervical smear is analysed by a pathologist via a visual subjective inspection using traditional microscopy. This is an 8-step process performed by several persons at different locations. Secondly, if positive, a molecular 4-step HPV test is performed. Results are available after 3 to 4 weeks causing anxiety and frustration for the patient. Typical instruments are expensive and have high related operational costs. Ovizio has designed a direct read vial allowing for the sample to be directly analysed without manipulation. The technology automatically generates objective data, identifying cells, detecting malicious cells and combines cytology and HPV in one test. This is a 3-step process: 1. sampling, 2. analysing, 3. report generation. The test is performed on a small low-cost device giving results in minutes rather than days allowing for near patient testing. A proof of concept and alpha prototype have been built with basic software algorithms. Several test have been performed at hospitals in Belgium and France resulting in two scientific publications and enthusiasm from key opinion leaders. The breakthrough technology transforms microscopic images into actionable data, corresponding to a market need of faster and improved testing, allowing healthcare organisations of member states to reduce costs and improve testing ratio’s. The company has a team that has done it before completed with highly skilled subject experts in the field and has launched 3 products laying the foundations for this project.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores